ライフサイエンスコーパス: neprilysin

1 ic peptides by inhibiting their breakdown by neprilysin.

2 ting vascular remodeling but are degraded by neprilysin.

3 exhibited specificity for ECE-2 compared to neprilysin.

4 erting enzyme, insulin-degrading enzyme, and neprilysin.

5 lysin inhibitor, attenuated these effects of neprilysin.

6 nhibit both the renin-angiotensin system and neprilysin.

7 ta (Abeta), and the Abeta-degrading protease neprilysin.

8 substrate, and pathophysiological aspects of neprilysin.

9 arget, we used inducible drivers to modulate neprilysin 1 (Nep1) and dAbeta expression in adult DPM n

10 ched for an interaction between Amnesiac and Neprilysin 1 (Nep1), a fly neprilysin involved in memory

11 functional relationship between Amnesiac and Neprilysin 1 (Nep1), a membrane peptidase involved in me

12 data reveal a functional interaction between neprilysin 1 and amyloid peptide, suggesting that nepril

13 lysin 1 and amyloid peptide, suggesting that neprilysin 1 degrades amyloid peptide.

14 we show that an increase in the level of the neprilysin 1 peptidase overcomes memory deficits induced

15 One gain was observed for the Neprilysin-1 (Nep1) gene, which has evolved a unique exp

16 Of particular interest is the NEP homolog neprilysin 2 (NEP2), which is thiorphan/phosphoramidon-s

17 tions, Abeta1-40 (20 muM) was incubated with neprilysin (300 ng/ml), an endopeptidase known to hydrol

18 opeptidase related in amino acid sequence to neprilysin, a mammalian cell-surface peptidase involved

19 is important to determine whether increased neprilysin activity also diminishes the levels of pathog

20 beta1 antagonist bisoprolol inhibited renal neprilysin activity and increased circulation NP levels

21 explore whether substances that can elevate neprilysin activity could be a rational option for treat

22 ed that RF-RDN significantly inhibited renal neprilysin activity in SHR and WKY with HF.

23 Islet neprilysin activity was inhibited or up-regulated using

24 l nerves on kidney function attenuates renal neprilysin activity, augments circulating NP levels, red

25 is mediated, at least in part, by decreased neprilysin activity.

26 ion of insulin-like peptides is regulated by neprilysin activity.

27 rs individually and found that inhibition of neprilysin alone could enhance enkephalin responses to t

28 al development, was found to also target the neprilysin, aminopeptidase, and dipeptidylpeptidase clan

29 Now we studied the effect of neprilysin, an Abeta-degrading enzyme, on development of

30 We sought to determine whether neprilysin, an amyloid-degrading enzyme, is present in i

31 ding enzyme, endothelin-converting enzyme-1, neprilysin and alpha-secretase.

32 ning proved that Phe(3) is a key residue for neprilysin and aminopeptidase N (AP-N) ectoenkephalinase

33 combining NP degradation inhibition through neprilysin and angiotensin receptor blockade, has led to

34 wo of the three angiotensin-forming enzymes (neprilysin and endopeptidase 24.15) also contribute to t

35 Angiotensin-converting enzyme, neprilysin and endothelin-converting enzyme function as

36 in strongly decreased tissue availability of neprilysin and impaired enzymatic activity.

37 and spatial relationships between decreased neprilysin and increased cell growth.

38 m roles for endothelin-converting enzyme and neprilysin and indicate that reductions in these enzymes

39 tein, and its degradation by enzymes such as neprilysin and insulin degrading enzyme.

40 t was independent of mRNA/protein changes in neprilysin and insulin-degrading enzyme and, instead, ma

41 closely similar sites as wild-type Abeta by neprilysin and insulin-degrading enzyme, the two most wi

42 dation of Abeta peptides within microglia by neprilysin and related enzymes is dramatically enhanced

43 s revealed a global myocardial response, and neprilysin and the STAT family as key regulators of intr

44 pted us to search for an interaction between neprilysins and Drosophila Abeta (dAbeta), a cleavage pr

45 The high functional conservation of neprilysins and their substrates renders the characteriz

46 three enzymes: neutral endopeptidases 24.11 (neprilysin) and 24.15 and prolyl-endopeptidase 24.26.

47 by isolation of the enzyme that degrades it (neprilysin) and its inhibitors.

48 I and Ang-(1-7), together with cardiac ACE2, neprilysin, Ang II type 1 receptor (AT1), and mas recept

49 10 muM) were used to inhibit the activity of neprilysin, angiotensin-converting enzyme, or aminopepti

50 there has been no direct demonstration that neprilysin antagonizes the deposition of amyloid-beta in

51 Neprilysins are also required in the MB, reflecting the

52 Neprilysins are endopeptidases known to degrade a number

53 gical target for Nep1.SIGNIFICANCE STATEMENT Neprilysins are endopeptidases known to degrade a number

54 use Drosophila melanogaster to study whether neprilysins are involved in memory.

55 RNA interference, we show here that all four neprilysins are involved in middle-term and long-term me

56 Neprilysins are Type II metalloproteinases known to degr

57 Neprilysins are type II metalloproteinases known to degr

58 Finally, we provide evidence about soluble neprilysin as a biomarker surrogate in patients with hea

59 We next highlight the value of neprilysin as a biotarget and weigh the clinical benefit

60 suggest that the recombinant brain-targeted neprilysin, ASN12, may be an effective treatment for AD

61 an increase in the Abeta-degrading protease neprilysin at the cell surface and a concomitant increas

62 (2, 4-dinitrophenyl) is also a substrate for neprilysin, but is hydrolyzed 10-fold more efficiently b

63 Treatment with recombinant neprilysin, but not enzymatically inactive neprilysin, r

64 nificant regional association with BACE1 and neprilysin, but not PSD95 that regionally associated wit

65 genetically engineered form of the protease neprilysin completely arrest amyloid deposition in an ag

66 Median neprilysin concentration in 1,069 patients was 0.642 ng/

67 In age-adjusted Cox regression analyses, neprilysin concentrations were significantly associated

68 Neprilysin contributes to free fatty acid (FFA)-induced

69 This finding suggests that neprilysin could facilitate neuroreplacement therapy wit

70 In summary, neprilysin decreases islet amyloid deposition by inhibit

71 proves learning and memory deficits, whereas neprilysin deficiency aggravates the behavioral phenotyp

72 ely, angiotensin-(1-2) enhanced GSIS in both neprilysin-deficient and wild-type islets.

73 In neprilysin-deficient mouse islets, angiotensin-(1-7) and

74 under nonpathological conditions, mammalian neprilysins degrade amyloid peptide to ensure memory for

75 er, a more widely expressed islet peptidase, neprilysin, degrades angiotensin-(1-7) into several pept

76 at the mechanism for protection conferred by neprilysin deletion involves prevention of reduced calci

77 lysin on plaques and oligomers suggests that neprilysin-dependent degradation of Abeta affects plaque

78 proach to test the alternate hypothesis that neprilysin depletion increases chronic hypoxic pulmonary

79 eficient mouse islets, angiotensin-(1-7) and neprilysin-derived degradation products angiotensin-(1-4

80 odel of ECE-2 using the crystal structure of neprilysin (EC 3.4.24.11) as a template.

81 The fly genome contains five neprilysin-encoding genes, four of which are expressed i

82 In Drosophila, several neprilysins expressed in the brain are required for midd

83 We previously showed that all four neprilysins expressed in the Drosophila brain are involv

84 Functional studies involving neprilysin-expressing vascular endothelial cells demonst

85 Concomitant phenotypes of altered neprilysin expression included impaired food intake, red

86 CG4721 encodes a neprilysin family metalloprotease that is highly up-regu

87 Kell is classified in the neprilysin family of zinc endopeptidases, and XK has str

88 re not conserved in the other members of the neprilysin family, and based on the hypothesis that one

89 nase CD10/neutral endopeptidase 24.11 ([NEP] neprilysin) functions as part of a regulatory loop to co

90 Four neprilysin genes are expressed in adult Drosophila Using

91 Loss of neprilysin had no effect on baseline airway or alveolar

92 The endopeptidase neprilysin has been successfully used to reduce the accu

93 Neprilysin has recently been implicated as a major extra

94 apparent structural similarities, ECE-1 and neprilysin have been considered to differ significantly

95 drug classes, namely inhibitors of DPP IV or neprilysin, have been developed.

96 Natriuretic peptides are substrates of neprilysin; hence, B-type natriuretic peptide (BNP) conc

97 CAP peptide is cleaved by the human membrane neprilysin hNEP, we searched for an interaction between

98 A screen for corresponding substrates of the neprilysin identified distinct peptides that regulate in

99 pinephrine, angiotensin II, aldosterone, and neprilysin) impair insulin sensitivity and contribute to

100 utations in MME encoding the metalloprotease neprilysin in 19 index case subjects diagnosed with axon

101 o assess the presence of circulating soluble neprilysin in a real-life cohort of HF patients and corr

102 d cardiomyocytes confirmed the importance of neprilysin in ameliorating PAO accumulation.

103 und zinc-metallopeptidase that is related to neprilysin in amino acid sequence.

104 ion of STAT1 and CASP3 and downregulation of neprilysin in both zones, suggesting r-I/R induced intri

105 Overexpression of the Abeta-degrading enzyme neprilysin in brains of human amyloid precursor protein

106 n beta-secretase activity and a reduction of neprilysin in female mice compared to males; this sugges

107 Identification of circulating neprilysin in HF patients and the positive association o

108 findings suggest that targeting the role of neprilysin in IAPP fibril assembly, in addition to IAPP

109 Importantly, adenoviral overexpression of neprilysin in islets cultured without FFA reproduces the

110 These data further support a role for neprilysin in regulating cerebral amyloid deposition and

111 suggesting the sustained elevation of islet neprilysin in these mice was a compensatory mechanism ai

112 Neprilysins in particular are the major amyloid-beta pep

113 Together, our data establish a role for neprilysins in two specific memory phases and further sh

114 rading enzymes (insulin-degrading enzyme and neprilysin) in APP/CCL2 and APP mice were indistinguisha

115 Neprilysin increased the number of neurospheres that for

116 romoting carcinogenesis, decreased levels of neprilysin increases inflammation and neuroendocrine cel

117 2 (angiotensin-converting enzyme 2) and NEP (neprilysin) induce the alternative, and potentially reno

118 ss spectrometry, which failed to demonstrate neprilysin-induced cleavage.

119 and signaling, whereas exogenous recombinant neprilysin inhibited signaling.

120 Angiotensin receptor-neprilysin inhibition (ARNI) improves mortality among pa

121 Angiotensin receptor neprilysin inhibition (ARNI) therapy provided incrementa

122 Although neprilysin inhibition appeared to have greater effects o

123 These data suggest that neprilysin inhibition attenuates the risk of hyperkalemi

124 (Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Redu

125 odel, and data from the Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ej

126 We assessed the renal effects of angiotensin/neprilysin inhibition in patients who have heart failure

127 results, and further suggest the benefit of neprilysin inhibition may be partially mediated by incre

128 Lastly, the impact of neprilysin inhibition on mid-regional pro-ANP (MR-proANP

129 Angiotensin-neprilysin inhibition prevents the clinical progression

130 Thus, neprilysin inhibition reduces hypertension, ultimately l

131 Recently, the addition of neprilysin inhibition to angiotensin receptor blockade h

132 Analysis of the effect of neprilysin inhibition was 1 of 12 pre-specified subgroup

133 comparison, NT-proBNP is not a substrate of neprilysin inhibition, and thus may lead to less clinica

134 Following neprilysin inhibition, islet amyloid deposition and beta

135 chronic hypoxic pulmonary hypertension with neprilysin inhibition.

136 retic peptide (BNP) concentrations rise with neprilysin inhibition.

137 Angiotensin receptor-neprilysin inhibitor (ARNI) prescription in the United S

138 Angiotensin receptor blocker-neprilysin inhibitor (ARNi) therapy improves the prognos

139 betes status, age, sex, angiotensin receptor neprilysin inhibitor (ARNI) treatment, New York Heart As

140 in receptor blocker, or angiotensin receptor-neprilysin inhibitor (ARNI) use decreased over time, and

141 receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineraloc

142 CZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), in patients with this disor

143 Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI), mineralocorticoid receptor

144 sin receptor blocker (valsartan [VAL]) and a neprilysin inhibitor (sacubitril [SAC]), was shown to be

145 tensin receptor blocker/angiotensin receptor-neprilysin inhibitor + beta-blocker + mineralocorticoid

146 combined angiotensin receptor antagonist and neprilysin inhibitor addresses 2 of the pathophysiologic

147 Angiotensin receptor-neprilysin inhibitor appeared to consistently reduce the

148 The neprilysin inhibitor component of LCZ696, LBQ657, inhibi

149 ptor antagonist in 30%, angiotensin receptor-neprilysin inhibitor in 2%, and ivabradine in 2%.

150 We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angi

151 l size suggest that the angiotensin receptor neprilysin inhibitor LCZ696 may reduce this measure of m

152 NT) trial, in which the angiotensin receptor neprilysin inhibitor LCZ696 reduced markers of heart fai

153 We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients w

154 re (HF) treated with an angiotensin receptor neprilysin inhibitor lived longer without being hospital

155 Angiotensin receptor neprilysin inhibitor measure performance was significant

156 cardiac hypertrophy than either stand-alone neprilysin inhibitor or angiotensin receptor blocker.

157 blocker, or any dose of angiotensin receptor neprilysin inhibitor plus any dose of mineralocorticoid

158 giotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio i

159 stigated the biological effects of ARNi with neprilysin inhibitor sacubitril and angiotensin receptor

160 The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduc

161 The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated

162 in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effec

163 d that a new angiotensin receptor antagonist-neprilysin inhibitor was superior to an angiotensin-conv

164 reases in NT-proBNP following the use of the neprilysin inhibitor were extremely rare.

165 ospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzy

166 ospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme

167 ospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker o

168 on treatment with ARNI (angiotensin receptor/neprilysin inhibitor) therapy or left ventricular assist

169 ive Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting

170 medication (angiotensin II receptor blocker neprilysin inhibitor).

171 ortality when comparing angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antag

172 nhibitor or ARB+BB, and angiotensin receptor-neprilysin inhibitor+BB+mineralocorticoid receptor antag

173 tensin receptor blocker/angiotensin receptor-neprilysin inhibitor, 20% on mineralocorticoid receptor

174 tensin receptor blocker/angiotensin receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid rec

175 a-blocker and one of an angiotensin receptor-neprilysin inhibitor, angiotensin-converting enzyme inhi

176 Phosphoramidon, a neprilysin inhibitor, attenuated these effects of nepril

177 alsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality i

178 bines an angiotensin receptor blocker with a neprilysin inhibitor, is well tolerated, and represents

179 esized that angiotensin receptor blocker and neprilysin inhibitor, sacubitril/valsartan (Sac/Val, LCZ

180 ive Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-

181 ive Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-

182 ive Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-

183 ive Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ARB [Angiotensin Receptor Blo

184 ive Comparison of ARNI [angiotensin receptor/neprilysin inhibitor] With ARB [angiotensin-receptor blo

185 combination of angiotensin receptor blocker/neprilysin inhibitors (ARNi)+beta-blockers (BB)+sodium-g

186 Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking angiotensi

187 antagonists (MRA), and angiotensin receptor-neprilysin inhibitors (ARNI), have not been studied in a

188 Combined angiotensin receptor blocker neprilysin inhibitors (ARNIs) have been associated with

189 tor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotran

190 acological therapy with angiotensin receptor-neprilysin inhibitors and device therapy deserves furthe

191 medications, especially angiotensin receptor-neprilysin inhibitors and sodium-glucose cotransporter-2

192 rrent use of angiotensin-(1-7) compounds and neprilysin inhibitors as therapies for diabetes.

193 Combined treatment with both SGLT2 and neprilysin inhibitors can be expected to yield substanti

194 ceptor antagonists, and angiotensin receptor-neprilysin inhibitors were used in 85.1%, 44.4%, 28.6%,

195 nhibitors and ANG (angiotensin) II blockers, neprilysin inhibitors, and aldosterone antagonists.

196 in system inhibitors or angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid

197 and weigh the clinical benefits of synthetic neprilysin inhibitors, either alone or in combination wi

198 cular pathways causing angioedema induced by neprilysin inhibitors, that is, sacubitril, are unclear,

199 inical data from investigations of synthetic neprilysin inhibitors.

200 nhibitors but insensitive to proteasomal and neprilysin inhibitors.

201 n patients treated with angiotensin receptor-neprilysin inhibitors.

202 's disease (AD) markers, synaptophysin, APP, neprilysin, insulin-degrading enzyme and transthyretin i

203 including the endothelin-converting enzymes, neprilysin, insulin-degrading enzyme, and plasmin.

204 ween Amnesiac and Neprilysin 1 (Nep1), a fly neprilysin involved in memory.

205 Neprilysin is a cell surface peptidase that catalyticall

206 Together, these findings demonstrate that neprilysin is a factor associated with islet amyloid acc

207 Neprilysin is a membrane-bound enzyme that breaks down n

208 Neprilysin is a metallopeptidase known to degrade amyloi

209 Neprilysin is a transmembrane metalloendopeptidase that

210 In sum, neprilysin is a versatile, veteran player returning yet

211 Neprilysin is a zinc-dependent endopeptidase.

212 Neprilysin is an endopeptidase that degrades vasoactive

213 ing live cell imaging, and that the protease neprilysin is involved in reduction of intraneuronal bet

214 Although neprilysin is known to degrade beta-amyloid, we observed

215 tan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-b

216 This indicates neprilysin is the predominant peptidase responsible for

217 time that with prolonged FFA exposure, islet neprilysin is upregulated and this is associated with re

218 that require further research before soluble neprilysin is used clinically.

219 ctivity of an Abeta-degrading endopeptidase, neprilysin, is elevated in the brains of "enriched" mice

220 elevated in endothelin-converting enzyme and neprilysin knock-out mice, and inhibitors of these enzym

221 issue, a lentiviral vector expressing human neprilysin (Lenti-Nep) was tested in transgenic mouse mo

222 Associations between neprilysin level and a composite endpoint that included

223 Lung-targeted strategies to increase neprilysin levels could have therapeutic benefits in the

224 eal-life cohort of HF patients and correlate neprilysin levels with outcomes.

225 Rather, neprilysin may act by reducing hIAPP fibrillogenesis, wh

226 These data suggest that neprilysin may be protective against chronic hypoxic pul

227 l reduction of extracellular Abeta levels by neprilysin may facilitate development of HNPCs into neur

228 on and suggest that interventions to inhibit neprilysin may improve beta-cell function in obese human

229 le blood RNA expression of gene encoding for Neprilysin (MME) and miR-425 among blacks than whites.

230 To determine if neprilysin modulated amyloid deposition by cleaving hIAP

231 In contrast, neprilysin mRNA and activity did not decrease in amyloid

232 t in islets, including beta-cells, and islet neprilysin mRNA and activity were found to decline with

233 e of the treatments had an effect on cardiac neprilysin mRNA.

234 Neprilysin (NEP) and angiotensin-converting enzyme (ACE)

235 t AD is with Abeta-degrading enzymes such as neprilysin (NEP) and insulin-degrading enzyme (IDE).

236 ression and execution of two endopeptidases, neprilysin (NEP) and insulin-degrading enzyme.

237 Neprilysin (NEP) appears to be the most potent Abeta pep

238 mily of Zn2+ metallopeptidases which include neprilysin (NEP) as prototype, has raised important ques

239 ression of insulin-degrading enzyme (IDE) or neprilysin (NEP) in neurons significantly reduces brain

240 creased expression of Abeta-degrading enzyme neprilysin (NEP) in primary neuronal cultures.

241 an ethyl ester prodrug of LBQ657, the active neprilysin (NEP) inhibitor, and a component of LCZ696 (s

242 The endopeptidase neprilysin (NEP) is a major amyloid-beta (Abeta) degradi

243 Neprilysin (NEP) is a naturally occuring enzyme that bre

244 Neprilysin (NEP) is a zinc-dependent metalloprotease tha

245 Neprilysin (NEP) is an endopeptidase, which has an impor

246 s evidence that the Abeta-degrading protease neprilysin (NEP) is down-regulated in normal aging and L

247 Neprilysin (NEP) is one of the rate-limiting Abeta-degra

248 The Abeta-degrading enzyme neprilysin (NEP) is the best known target of these inhib

249 Neprilysin (NEP) is the dominant Abeta peptide-degrading

250 icrovessels and the Abeta-degrading protease neprilysin (NEP) occurred 14-21 d after a substantial de

251 abolism in kidney homogenates, we identified neprilysin (NEP) to be a major source of renal Ang-(1-7)

252 tein and mRNA for the Abeta-degrading enzyme neprilysin (NEP) was found, whereas various Abeta-cleari

253 Insulysin (IDE) and neprilysin (NEP) were found to be inactivated by oxidati

254 Angiotensin-converting enzyme 2 (ACE-2), neprilysin (NEP), and plasma kallikrein (KLKB1) cleave a

255 lin-derived peptides by proteases, including neprilysin (NEP).

256 The neprilysin (NEP)/endothelin-converting enzyme (ECE) fami

257 by two membrane-bound Zn-metallopeptidases, neprilysin (NEP, EC 3.4.24.11) and aminopeptidase N (APN

258 levels of the metallomembrane endopeptidase neprilysin, normal levels were maintained in the exercis

259 After chronic hypoxia, neprilysin-null mice exhibited exaggerated pulmonary hyp

260 Smooth muscle cells from neprilysin-null pulmonary arteries had increased prolife

261 This effect might result from degradation by neprilysin of endogenous Abeta produced and secreted by

262 The differential effect of neprilysin on plaques and oligomers suggests that nepril

263 re resistant to a 1-h incubation with either neprilysin or insulin degrading enzyme, whereas the mono

264 al cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocar

265 In mouse models of Alzheimer's disease, neprilysin overexpression improves learning and memory d

266 Neprilysin overexpression reduced soluble Abeta levels b

267 ion of the renin-angiotensin-aldosterone and neprilysin pathways, as well as the limitations of these

268 ux and GSIS, suggesting that upregulation of neprilysin per se mediates insulin secretory dysfunction

269 s a substrate specificity similar to that of neprilysin, preferring to cleave substrates at the amino

270 These data indicate that neprilysin proteolytically inactivates fibroblast growth

271 hout exogenous Abeta1-40, the treatment with neprilysin reduced the number of developing colonies.

272 We previously showed that the enzyme neprilysin reduces islet amyloid deposition and thereby

273 omprehensive multivariable analyses, soluble neprilysin remained significantly associated with both t

274 mpared with controls, which was decreased by neprilysin replacement.

275 Neprilysin research has essentially focused on their rol

276 a specific inhibitor or adenovirus encoding neprilysin, respectively.

277 t neprilysin, but not enzymatically inactive neprilysin, resulted in a slight increase in basic fibro

278 Neprilysin's inability to prevent learning and memory de

279 To find out whether dAbeta was a neprilysin's target, we used inducible drivers to modula

280 In this study, we found that neprilysin selectively controls endogenous opioid concen

281 Genetic ablation of neprilysin specifically protects against FFA-induced imp

282 e rapid, comparable with that of other known neprilysin substrates.

283 t)Lu-DOTA-PP-F11N is less of a substrate for neprilysins than the other analogs, whereas intracellula

284 We previously characterized a recombinant neprilysin that contained a 38-amino acid brain-targetin

285 perineuronal net (PNN) and Mme encoding for Neprilysin, the enzyme degrading amyloid beta-peptides.

286 erted by esterases to LBQ657, which inhibits neprilysin, the enzyme responsible for the degradation o

287 We previously demonstrated neprilysin to be present in pancreatic islets and now so

288 estion, we crossed hAPP transgenic mice with neprilysin transgenic mice and analyzed their offspring.

289 This effect of neprilysin was associated with reduced amounts of the mo

290 Circulating soluble neprilysin was measured with a modified sandwich immunoa

291 ving hIAPP, analysis of hIAPP incubated with neprilysin was performed by mass spectrometry, which fai

292 Neprilysin was present in islets, including beta-cells,

293 ed by 54 and 75%, respectively, whereas when neprilysin was up-regulated islet amyloid deposition and

294 Combined inhibition of SGLT2 and neprilysin was well-tolerated.

295 ECE-1, unlike neprilysin, was found to have minimal activity against s

296 Neprilysin weakly but significantly correlated with age

297 rading enzymes, insulin degrading enzyme and neprilysin, were unchanged.

298 ding enzyme, the endogenous metallopeptidase neprilysin, which is fused to albumin to extend plasma h

299 HF patients and the positive association of neprilysin with cardiovascular mortality and morbidity f

300 not wild-type neurons show reduced levels of neprilysin with time in culture.